muraglitazar has been researched along with rosiglitazone in 18 studies
| Studies (muraglitazar) | Trials (muraglitazar) | Recent Studies (post-2010) (muraglitazar) | Studies (rosiglitazone) | Trials (rosiglitazone) | Recent Studies (post-2010) (rosiglitazone) |
|---|---|---|---|---|---|
| 85 | 10 | 25 | 4,749 | 556 | 1,818 |
| Protein | Taxonomy | muraglitazar (IC50) | rosiglitazone (IC50) |
|---|---|---|---|
| CDGSH iron-sulfur domain-containing protein 1 | Rattus norvegicus (Norway rat) | 1.1 | |
| Bile salt export pump | Homo sapiens (human) | 4.5853 | |
| Carbonic anhydrase 2 | Homo sapiens (human) | 4.069 | |
| Peroxisome proliferator-activated receptor alpha | Mus musculus (house mouse) | 0.08 | |
| Thromboxane-A synthase | Homo sapiens (human) | 3.56 | |
| Amine oxidase [flavin-containing] B | Homo sapiens (human) | 0.832 | |
| Peroxisome proliferator-activated receptor gamma | Homo sapiens (human) | 0.2481 | |
| Mu-type opioid receptor | Cavia porcellus (domestic guinea pig) | 0.038 | |
| ATP-binding cassette sub-family C member 8 | Homo sapiens (human) | 0.048 | |
| ATP-sensitive inward rectifier potassium channel 11 | Homo sapiens (human) | 0.048 | |
| Sodium/bile acid cotransporter | Homo sapiens (human) | 5.1 | |
| CDGSH iron-sulfur domain-containing protein 2 | Homo sapiens (human) | 2.29 | |
| CDGSH iron-sulfur domain-containing protein 1 | Homo sapiens (human) | 0.731 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (50.00) | 29.6817 |
| 2010's | 8 (44.44) | 24.3611 |
| 2020's | 1 (5.56) | 2.80 |
| Authors | Studies |
|---|---|
| Henke, BR | 1 |
| Biller, SA; Cap, M; Chandrasena, G; Chang, SY; Chen, S; Cheng, L; Cheng, PT; Devasthale, PV; Doweyko, A; Farrelly, D; Golla, R; Grover, G; Hariharan, N; Harrity, T; Humphreys, WG; Jeon, Y; Ma, Z; Moore, L; Qu, F; Ren, J; Ryono, DE; Sasseville, VG; Seethala, R; Selan, F; Shao, C; Sleph, P; Sun, W; Tieman, A; Wang, W; Wetterau, JR; Zhang, H | 1 |
| Chandrasena, G; Chen, S; Cheng, L; Cheng, PT; Devasthale, PV; Doweyko, AM; Farrelly, D; Golla, R; Grover, G; Hariharan, N; Jeon, Y; Ma, Z; Moore, L; Qu, F; Ryono, DE; Seethala, R; Sleph, P; Sun, W; Wang, W; Zhang, H | 1 |
| Cap, M; Chang, C; Cheng, PT; Chu, C; Devasthale, P; Doweyko, AM; Farrelly, D; Gu, L; Hariharan, N; Harrity, T; Hosagrahara, V; Kadiyala, P; Kunselman, L; Lippy, J; Locke, K; Morgan, N; Muckelbauer, J; O'Malley, K; Ponticiello, R; Ryono, D; Wang, W; Zahler, R; Zebo, R; Zhang, L | 1 |
| Ahn, BN; Bae, MH; Chong, W; Han, T; Kim, E; Kim, EJ; Kim, JK; Kim, MK; Kim, SH; Lee, CH; Lim, JI; Moon, HS; Park, CS; Shim, HJ; Shin, CY; Shin, YA; Son, MH | 1 |
| Chae, YN; Chang, DJ; Jung, JW; Kang, HJ; Kim, MK; Kim, NJ; Koo, BW; Le, TV; Lee, KO; Li, F; Lim, JI; Moon, SH; Paek, SM; Park, HJ; Ryu, JS; Shin, CY; Shin, DH; Suh, YG | 1 |
| Kagechika, K; Kubo, H; Shibata, Y; Usui, H; Yamaguchi, M | 1 |
| Berthelot, P; Beucher-Gaudin, M; Caignard, DH; Dacquet, C; Farce, A; Géant, A; Hennuyer, N; Ktorza, A; Lebegue, N; Leclerc, V; Pirat, C; Staels, B; Zanirato, G | 1 |
| Amaudrut, J; Barth, M; Binet, J; Boubia, B; Broqua, P; Chatar, M; Dodey, P; Ferry, S; Gauthier, E; Guillier, F; Jacquier, E; Junien, JL; Lacombe, O; Legendre, C; Lepais, V; Llacer, J; Luccarini, JM; Masson, P; Montalbetti, C; Mounier, L; Peralba, P; Poupardin, O; Thourigny, A; Wettstein, G | 1 |
| Adams, WJ; Artman, GD; Colca, JR; Gadwood, RC; Kletzien, RF; Larsen, SD; Lee, PH; McDonald, WG; Parker, TT; Tanis, SP; Zeller, JB | 1 |
| Biller, S; Cap, M; Chen, S; Cheng, PT; Chu, C; Devasthale, P; Farrelly, D; Fenderson, W; Gregg, R; Gu, L; Hariharan, N; Harrity, T; Jeon, Y; Kunselman, L; Mookhtiar, KA; Ponticiello, R; Qu, F; Ren, J; Ryono, D; Seethala, R; Shao, C; Tieman, A; Wang, W; Wetterau, J; Yang, WP; Zhang, H; Zhou, M | 1 |
| Bansal, VS; Bora, RS; Gupta, A; Khanna, V; Khattar, SK; Mittra, S; Priyadarsiny, P; Roy, S; Saini, KS; Sangle, G; Sattigeri, J; Sharma, L; Sharma, S; Tandon, R | 1 |
| Kim, JK; Kim, MK; Kim, NJ; Koo, BW; Lee, KO; Li, F; Lim, JI; Min, KH; Park, HJ; Suh, YG; Yoo, JK | 1 |
| Claude, N; Guillouzo, A; Renaud, MP; Rogue, A; Spire, C | 1 |
| Amacher, DE; Boucher, GG; Francone, O; Kerlin, RL; Morton, D; Pettersen, JC; Pruimboom-Brees, IM; Will, Y | 1 |
| Brito, JP; Gionfriddo, MR; Leppin, AL; Montori, VM; Morey-Vargas, OL; Murad, MH | 1 |
| Amoroso, R; Maccallini, C; Mollica, A | 1 |
| Califf, RM; Demets, D; George, JT; Gerstein, HC; Granger, C; Green, JB; Hobbs, T; Holman, RR; Lawson, FC; Leiter, LA; McGuire, DK; McMurray, J; Pagidipati, NJ; Pfeffer, MA; Reusch, J; Riesmeyer, JS; Roe, MT; Rosenberg, Y; Sharma, A; Temple, R; Wiviott, S | 1 |
3 review(s) available for muraglitazar and rosiglitazone
| Article | Year |
|---|---|
Peroxisome proliferator-activated receptor alpha/gamma dual agonists for the treatment of type 2 diabetes.
Topics: Animals; Diabetes Mellitus, Type 2; Humans; Hyperglycemia; Hypoglycemic Agents; Models, Molecular; Molecular Structure; Receptors, Cytoplasmic and Nuclear; Transcription Factors | 2004 |
Systematic reviews to ascertain the safety of diabetes medications.
Topics: Acidosis, Lactic; Blood Glucose; Diabetes Mellitus, Type 2; Evidence-Based Medicine; Female; Fractures, Bone; Glycated Hemoglobin; Glycine; Humans; Hypoglycemic Agents; Male; Meta-Analysis as Topic; Metformin; Oxazoles; Pancreatic Neoplasms; Risk Assessment; Rosiglitazone; Thiazolidinediones; Urinary Bladder Neoplasms | 2014 |
The Positive Regulation of eNOS Signaling by PPAR Agonists in Cardiovascular Diseases.
Topics: Animals; Cardiovascular Diseases; Glycine; Humans; Nitric Oxide Synthase Type III; Oxazoles; Peroxisome Proliferator-Activated Receptors; Rosiglitazone; Signal Transduction; Thiazolidinediones | 2017 |
15 other study(ies) available for muraglitazar and rosiglitazone
| Article | Year |
|---|---|
Design and synthesis of N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5- methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine [Muraglitazar/BMS-298585], a novel peroxisome proliferator-activated receptor alpha/gamma dual agonist with efficacious glucose and
Topics: Adipocytes; Animals; Blood Glucose; Cell Line; Diabetes Mellitus, Type 2; Fatty Acids; Glycine; Humans; Hyperlipidemias; Hypoglycemic Agents; Hypolipidemic Agents; Insulin; Male; Mice; Mice, Obese; Oxazoles; PPAR alpha; PPAR gamma; Transcriptional Activation; Triglycerides | 2005 |
Discovery of tertiary aminoacids as dual PPARalpha/gamma agonists-I.
Topics: Amino Acids; Animals; Blood Glucose; Glycine; Hypoglycemic Agents; Hypolipidemic Agents; Mice; Mice, Inbred Strains; PPAR alpha; PPAR gamma; Structure-Activity Relationship | 2007 |
Discovery of azetidinone acids as conformationally-constrained dual PPARalpha/gamma agonists.
Topics: Administration, Oral; Animals; Azetidines; Biological Availability; Copper; Crystallography, X-Ray; Cytochrome P-450 Enzyme Inhibitors; Diabetes Mellitus, Experimental; Dyslipidemias; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Glucose; Mice; Mice, Mutant Strains; Molecular Structure; PPAR alpha; PPAR gamma; Protein Conformation; Stereoisomerism; Structure-Activity Relationship; Triglycerides | 2008 |
Design, synthesis, and evaluation of novel aryl-tetrahydropyridine PPARalpha/gamma dual agonists.
Topics: Animals; Combinatorial Chemistry Techniques; Diabetes Mellitus, Type 2; Disease Models, Animal; Drug Design; Mice; Molecular Structure; PPAR alpha; PPAR gamma; Pyridines; Rats; Rats, Sprague-Dawley | 2008 |
Design, synthesis, and biological evaluation of novel constrained meta-substituted phenyl propanoic acids as peroxisome proliferator-activated receptor alpha and gamma dual agonists.
Topics: Animals; Cell Line; Drug Design; Humans; Isoxazoles; Male; Mice; Mice, Inbred C57BL; Models, Molecular; Molecular Structure; Phenylpropionates; PPAR alpha; PPAR gamma; Stereoisomerism; Structure-Activity Relationship; Transcriptional Activation | 2008 |
Design, synthesis and evaluation of novel zwitterionic compounds as PPARα/γ dual agonists (1).
Topics: Animals; Blood Glucose; Drug Design; Mice; PPAR alpha; PPAR gamma; Structure-Activity Relationship; Thiazolidinediones; Triglycerides; Weight Gain | 2012 |
Anti-diabetic activity of fused PPARγ-SIRT1 ligands with limited body-weight gain by mimicking calorie restriction and decreasing SGK1 expression.
Topics: Animals; Body Weight; Caloric Restriction; Cells, Cultured; Chlorocebus aethiops; COS Cells; Dose-Response Relationship, Drug; Gene Expression Profiling; Hypoglycemic Agents; Immediate-Early Proteins; Ligands; Male; Mice; Mice, Obese; Molecular Docking Simulation; Molecular Structure; PPAR gamma; Protein Serine-Threonine Kinases; Sirtuin 1; Structure-Activity Relationship | 2017 |
Design, Synthesis, and Evaluation of a Novel Series of Indole Sulfonamide Peroxisome Proliferator Activated Receptor (PPAR) α/γ/δ Triple Activators: Discovery of Lanifibranor, a New Antifibrotic Clinical Candidate.
Topics: Animals; Benzothiazoles; Carbon Tetrachloride Poisoning; Cell Line; Drug Discovery; Fibrosis; Hepatocytes; High-Throughput Screening Assays; Humans; Hypoglycemic Agents; Indoles; Mice; Mice, Inbred C57BL; Models, Molecular; Molecular Structure; Non-alcoholic Fatty Liver Disease; Peroxisome Proliferator-Activated Receptors; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship; Sulfonamides | 2018 |
PPARγ-sparing thiazolidinediones as insulin sensitizers. Design, synthesis and selection of compounds for clinical development.
Topics: Dose-Response Relationship, Drug; Drug Design; Humans; Insulin Resistance; Molecular Structure; PPAR gamma; Structure-Activity Relationship; Thiazolidinediones | 2018 |
Muraglitazar, a novel dual (alpha/gamma) peroxisome proliferator-activated receptor activator, improves diabetes and other metabolic abnormalities and preserves beta-cell function in db/db mice.
Topics: Adiponectin; Animals; Blood Glucose; Corticosterone; Diabetes Mellitus, Type 2; Diet; Female; Glycine; Hyperlipidemias; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Liver; Mice; Obesity; Oxazoles; Peroxisome Proliferator-Activated Receptors; Rosiglitazone; Thiazolidinediones | 2006 |
Increase in weight induced by muraglitazar, a dual PPARalpha/gamma agonist, in db/db mice: adipogenesis/or oedema?
Topics: 3T3-L1 Cells; Adipocytes; Adipogenesis; Animals; Blood Glucose; Body Weight; Cell Differentiation; Edema; Epithelial Sodium Channels; Erythrocyte Count; Fatty Acids; Glycine; Hemoglobins; Kidney; Mice; Mice, Inbred Strains; Oxazoles; PPAR alpha; PPAR gamma; RNA, Messenger; Rosiglitazone; Sodium; Sodium-Potassium-Exchanging ATPase; Thiazolidinediones; Transcriptional Activation | 2007 |
Design, synthesis, and structure-activity relationship of carbamate-tethered aryl propanoic acids as novel PPARalpha/gamma dual agonists.
Topics: Carbamates; Chemistry, Pharmaceutical; Drug Design; Glycine; Models, Chemical; Models, Molecular; Molecular Structure; Oxazoles; PPAR alpha; PPAR gamma; Propionates; Rosiglitazone; Stereoisomerism; Structure-Activity Relationship; Thiazolidinediones; Transcriptional Activation | 2007 |
Comparative gene expression profiles induced by PPARγ and PPARα/γ agonists in rat hepatocytes.
Topics: Alkanesulfonates; Animals; Chromans; Gene Expression Profiling; Genes; Glycine; Hepatocytes; Humans; Male; Oligonucleotide Array Sequence Analysis; Oxazoles; Phenylpropionates; PPAR alpha; PPAR gamma; Rats; Rats, Wistar; Reverse Transcriptase Polymerase Chain Reaction; Rosiglitazone; Thiazolidinediones; Troglitazone | 2011 |
The development of subcutaneous sarcomas in rodents exposed to peroxisome proliferators agonists: hypothetical mechanisms of action and de-risking attitude.
Topics: Adipogenesis; Adipose Tissue, Brown; Adipose Tissue, White; Animals; Cell Differentiation; Chromans; Diabetes Mellitus, Type 2; DNA Damage; Glycine; Hypoglycemic Agents; Ion Channels; Mice; Mitochondria; Mitochondrial Proteins; Oxazoles; Oxidative Stress; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; Pioglitazone; PPAR alpha; PPAR gamma; Rats; RNA-Binding Proteins; Rodentia; Rosiglitazone; Sarcoma; Thermogenesis; Thiazolidinediones; Transcription Factors; Troglitazone; Uncoupling Protein 1 | 2012 |
Impact of Regulatory Guidance on Evaluating Cardiovascular Risk of New Glucose-Lowering Therapies to Treat Type 2 Diabetes Mellitus: Lessons Learned and Future Directions.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug-Related Side Effects and Adverse Reactions; Glucose; Glycated Hemoglobin; Glycine; Government Regulation; Humans; Hypoglycemic Agents; Oxazoles; Phenylbutazone; Practice Guidelines as Topic; Risk; Rosiglitazone; Tolbutamide; United States; United States Food and Drug Administration | 2020 |